List view / Grid view
16 February 2017 | By Niamh Marriott, Digital Editor
The European Commission has granted marketing authorisation for Eli Lilly and Incyte’s baricitinib (Olumiant) for the treatment of moderate to severe active rheumatoid arthritis (RA), in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs (DMARDs).
16 January 2017 | By Niamh Marriott, Digital Editor
The US Food and Drug Administration (FDA) has extended the review period for Eli Lilly and Incyte’s new drug application for investigational baricitinib, a once-daily oral medication for the treatment of moderate to severe rheumatoid arthritis (RA).
25 November 2016 | By Niamh Louise Marriott, Digital Content Producer
J is for Joint Pain - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in this chronic joint pain research...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
1 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The FDA approval is based on analytical, nonclinical, and clinical data confirming that Erelzi is highly similar to the US-licensed reference product. Clinical studies included four comparative pharmacokinetic (PK) studies in 216 healthy volunteers and a confirmatory efficacy and safety similarity study in 531 patients with chronic plaque psoriasis...
1 August 2016 | By Sanofi / Regeneron Pharmaceuticals, Inc.
Sanofi and Regeneron Pharmaceuticals, Inc. have announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for sarilumab, an investigational human monoclonal antibody directed against the IL-6 receptor that is intended for the treatment of adult patients with moderately to severely active rheumatoid arthritis...
With Remsima being on the market for a year, European Pharmaceutical Review caught up with Celltrion Healthcare to find out more about biosimilars...
14 July 2016 | By Victoria White, Digital Content Producer
The Arthritis Advisory Committee voted unanimously in support of biosimilar etanercept for all five indications of the reference product...
12 July 2016 | By Victoria White, Digital Content Producer
Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable...
5 July 2016 | By Victoria White, Digital Content Producer
Celltrion is to develop laboratory tests that will enable physicians to identify when patients on an anti-TNF drug require a change of dose...
22 June 2016 | By Victoria White, Digital Content Producer
The rheumatoid arthritis testing market is forecast to rise from $338.5 million in 2015 to $399.5 million by 2022, according to GlobalData...
10 June 2016 | By Victoria White, Digital Content Producer
A study presented at EULAR showed that when antibodies develop in response to the infliximab, they also cross-react with the biosimilar of infliximab...
Lilly and Incyte have announced new data for baricitinib in rheumatoid arthritis (RA) at the Annual European Congress of Rheumatology (EULAR 2016).
8 June 2016 | By Mandy Parrett, Editorial Assistant
Global biopharma company, Bristol-Myers Squibb, will present new data and offer insights into the field of rheumatoid arthritis at the Annual European Congress of Rheumatology (EULAR 2016) this week.
8 June 2016 | By Victoria White, Digital Content Producer
The SIRROUND-D study met both co-primary endpoints in evaluating treatment with sirukumab in adult patients with active rheumatoid arthritis...
